COST-EFFECTIVENESS OF ATORVASTATIN VERSUS SIMVASTATIN IN PREVENTION OF CARDIOVASCULAR EVENTS FROM A THAILAND SOCIETAL PERSPECTIVE

被引：0
|
作者：
Sukonthasarn, A. [1 ]
Thongtang, N. [2 ]
Ektare, V [3 ]
Du, F. [4 ]
Brizuela, G. [5 ]
Rustagi, S. [6 ]
Gao, X. [7 ]
机构：
[1] Bangkok Hosp Chiang Mai, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand
[3] Pharmerit India Private Ltd, Andheri East, MH, India
[4] Pharmerit Shanghai Co Ltd, Shanghai 31, Peoples R China
[5] A Viatris Co, Antipolo, Philippines
[6] A Viatris Co, Bangkok, Thailand
[7] Pharmerit, Waban, MA USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV21
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [21] Clinical and cost-effectiveness analysis of using atorvastatin for secondary stroke prevention: a Spanish perspective
    Mar, J.
    Vivancos, J.
    Rejas, J.
    Arrospide, A.
    Caro, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S695 - S695
  • [22] Cost-effectiveness of a heart failure management program from the societal perspective?
    Sendi, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) : 1850 - 1850
  • [23] COST-EFFECTIVENESS OF INTENSIVE LIPID LOWERING THERAPY WITH 80 MG OF ATORVASTATIN, VERSUS 10 MG OF ATORVASTATIN, FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN CANADA
    Wagner, Monika
    Goetghebeur, Mireille
    Merikle, Elizabeth
    Pandya, Ankur
    Chu, Paula
    Taylor, Douglas C. A.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2009, 16 (02): : E331 - E345
  • [24] Horizon and Perspective: Critical Choices in Estimating Cost-Effectiveness of Cardiovascular Prevention
    Auer, Reto
    Kazi, Dhruv S.
    Earnshaw, Stephanie R.
    Pignone, Michael
    Pletcher, Mark J.
    CIRCULATION, 2012, 126 (21)
  • [25] Evaluation of the cost-effectiveness of coronary stenting: A societal perspective
    Cohen, DJ
    AMERICAN HEART JOURNAL, 1999, 137 (05) : S133 - S137
  • [26] Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease
    Ferket, Bart S.
    Hunink, M. G. Myriam
    Khanji, Mohammed
    Agarwal, Isha
    Fleischmann, Kirsten E.
    Petersen, Steffen E.
    HEART, 2017, 103 (07) : 491 - 499
  • [27] Cost-effectiveness of atorvastatin 10 mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada
    Khoury, Hanane
    Wagner, Monika
    Merikle, Elizabeth
    Johnson, Scott J.
    Roberts, Craig
    CIRCULATION, 2008, 117 (21) : E450 - E450
  • [28] Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)
    M. Raikou
    A. McGuire
    H. M. Colhoun
    D. J. Betteridge
    P. N. Durrington
    G. A. Hitman
    H. A. W. Neil
    S. J. Livingstone
    V. Charlton-Menys
    J. H. Fuller
    Diabetologia, 2007, 50
  • [29] Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)
    Raikou, M.
    McGuire, A.
    Colhoun, H. M.
    Betteridge, D. J.
    Durrington, P. N.
    Hitman, G. A.
    Neil, H. A. W.
    Livingstone, S. J.
    Charlton-Menys, V.
    Fuller, J. H.
    DIABETOLOGIA, 2007, 50 (04) : 733 - 740
  • [30] Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial
    Chen, Jersey
    Bhatt, Deepak L.
    Dunn, Elizabeth Schneider
    Shi, Chunxue
    Caro, J. Jaime
    Mahoney, Elizabeth M.
    Gabriel, Sylvie
    Jackson, Joseph D.
    Topol, Eric J.
    Cohen, David J.
    VALUE IN HEALTH, 2009, 12 (06) : 872 - 879
12345